Clinical effect of Compound Danshen Dropping Pills combined with Tolvaptan in the treatment of patients with acute myocardial infarction and heart failure
WU Xiaoqiu HUANG Bin LIANG Shiwei
Department of Cardiology, Chongzuo People′s Hospital, Guangxi Zhuang Autonomous Region, Chongzuo 532200, China
Abstract：Objective To investigate the clinical effect of Compound Danshen Dropping Pills combined with Tolvaptan in the treatment of patients with acute myocardial infarction (AMI) complicated with heart failure and the effect on serum cardiac troponin I (cTnI), myoglobin (Myo) levels in patients. Methods A hundred patients with AMI and heart failure admitted to the Department of Cardiovascular Medicine of Chongzuo People′s Hospital from January 2019 to June 2021 were selected as subjects for retrospective analysis, and divided into control group (50 cases) and experimental group (50 cases) according to the different treatment methods. The control group applied the drug treatment of Toraputan alone, and the experimental group combined the Compound Danshen Dropping Pills based on the control group. The clinical efficacy, total incidence rate of adverse reactions (thirst, frequency of urine), remission duration of clinical symptoms (dyspnea, chest pain, lower limb edema), and serum cTnI levels, and serum Myo levels were compared between the two groups of patients. Results The total clinical effective rate of experimental group was higher than that of control group, and the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The relief time of dyspnea, chest pain and lower limb edema in the experimental group was shorter than that in the control group, and the difference was statistically significant (P<0.05). Before treatment, there were no significant differences in serum cTnI and Myo levels between the two groups (P>0.05). After treatment, the levels of serum cTnI and Myo in the two groups were lower than those before tretment, the differences were statistically significant (P<0.05). The levels of serum cTnI and Myo in experimental group were lower than those in control group after treatment, with statistical significances (P<0.05). Conclusion The application of Compound Danshen Drop Pills with Torvarutan for patients with AMI and heart failure can significantly improve their serum cTnI and Myo levels, while improving the clinical treatment effect and shortening the remission time of dyspnea, chest pain and lower limb edema.
京公网安备 11010502046607号